Showing results (11-20 of 22) with videos related to
Sort By:
Pageof 3
Cytometry. Part B, Clinical Cytometry|October 9, 2016
Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000Prashant R Tembhare, Sitaram Ghogale, Nisha Ghatwai, et al.Cytometry. Part B, Clinical Cytometry|August 20, 2020
Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusionPrashant R Tembhare, Gaurav Chatterjee, Twinkle Khanka, et al.Frontiers in Oncology|May 12, 2020
Post-induction Measurable Residual Disease Using Multicolor Flow Cytometry Is Strongly Predictive of Inferior Clinical Outcome in the Real-Life Management of Childhood T-Cell Acute Lymphoblastic Leukemia: A Study of 256 PatientsPrashant R Tembhare, Gaurav Narula, Twinkle Khanka, et al.Cytometry. Part B, Clinical Cytometry|September 8, 2020
Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-lymphoblastic leukemiaGaurav Chatterjee, Harshini Sriram, Sitaram Ghogale, et al.Journal for Immunotherapy of Cancer|May 23, 2020
Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapyPrashant Ramesh Tembhare, Harshini Sriram, Twinkle Khanka, et al.Cytometry. Part B, Clinical Cytometry|June 15, 2019
A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-106 and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 PatientsPrashant R Tembhare, Papagudi G Subramanian Pg, Sitaram Ghogale, et al.International Journal of Laboratory Hematology|January 12, 2021
Expression of CD304/neuropilin-1 in adult b-cell lymphoblastic leukemia/lymphoma and its utility for the measurable residual disease assessmentGaurav Chatterjee, Vishesh Dudakia, Sitaram Ghogale, et al.Cytometry. Part B, Clinical Cytometry|November 8, 2022
Expression levels and patterns of B-cell maturation antigen in newly diagnosed and relapsed multiple myeloma patients from Indian subcontinentHarshini Sriram, Florence Kunjachan, Twinkle Khanka, et al.British Journal of Haematology|September 3, 2021
Mimics and artefacts of measurable residual disease in a highly sensitive multicolour flow cytometry assay for B-lymphoblastic leukaemia/lymphoma: critical consideration for analysis of measurable residual diseaseGaurav Chatterjee, Harshini Sriram, Sitaram Ghogale, et al.European Journal of Haematology|September 14, 2023
15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia/lymphoma: Real-world applicability and challengesGaurav Chatterjee, Priyanka Dhende, Simpy Raj, et al.Pageof 3